Alector, Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company announced in the following press release that, “AL101 is Alector’s wholly-owned human monoclonal antibody and second product designed to restore levels of progranulin in the central nervous system. Progranulin is a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. Mutations that moderately reduce the expression levels of progranulin have been shown to increase the risk of developing Alzheimer’s disease and Parkinson’s disease, and increased progranulin levels have been demonstrated to be protective for these diseases in animal models.” Read the full article.
Company Website: https://alector.com